MX351305B - Antagonistas del receptor de mineralocorticoides. - Google Patents

Antagonistas del receptor de mineralocorticoides.

Info

Publication number
MX351305B
MX351305B MX2013008431A MX2013008431A MX351305B MX 351305 B MX351305 B MX 351305B MX 2013008431 A MX2013008431 A MX 2013008431A MX 2013008431 A MX2013008431 A MX 2013008431A MX 351305 B MX351305 B MX 351305B
Authority
MX
Mexico
Prior art keywords
formula
receptor antagonists
mineralocorticoid receptor
compounds
disclosed
Prior art date
Application number
MX2013008431A
Other languages
English (en)
Spanish (es)
Other versions
MX2013008431A (es
Inventor
Yuguang Wang
Robert J Devita
Peter J Sinclair
Dong-Ming Shen
Ping Lan
Kun Liu
Alejandro Crespo
Rudrajit Mal
Anthony Ogawa
Zhongxiang Sun
Zhicai Wu
Min Shu
John Qiang Tan
changhe Qi
Richard Beresis
Hong Shen
Ellen K Vande Bunte
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2013008431A publication Critical patent/MX2013008431A/es
Publication of MX351305B publication Critical patent/MX351305B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
MX2013008431A 2011-01-20 2012-01-19 Antagonistas del receptor de mineralocorticoides. MX351305B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434543P 2011-01-20 2011-01-20
PCT/CN2012/070597 WO2012097744A1 (en) 2011-01-20 2012-01-19 Mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
MX2013008431A MX2013008431A (es) 2013-08-12
MX351305B true MX351305B (es) 2017-10-09

Family

ID=46515166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008431A MX351305B (es) 2011-01-20 2012-01-19 Antagonistas del receptor de mineralocorticoides.

Country Status (11)

Country Link
US (2) US8933113B2 (OSRAM)
EP (1) EP2665707B1 (OSRAM)
JP (1) JP6078004B2 (OSRAM)
KR (1) KR20140009291A (OSRAM)
CN (1) CN103384661B (OSRAM)
AU (1) AU2012208837B2 (OSRAM)
CA (1) CA2824344A1 (OSRAM)
ES (1) ES2618812T3 (OSRAM)
MX (1) MX351305B (OSRAM)
RU (1) RU2598842C2 (OSRAM)
WO (1) WO2012097744A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351305B (es) * 2011-01-20 2017-10-09 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides.
WO2013135674A1 (en) * 2012-03-12 2013-09-19 Syngenta Participations Ag Insecticidal 2-aryl-acetamide compounds
RS56810B1 (sr) 2012-07-17 2018-04-30 Glaxosmithkline Ip No 2 Ltd Indolkarbonitrili kao selektivni modulatori androgen receptora
AR091731A1 (es) * 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
US10208043B2 (en) 2012-08-22 2019-02-19 Cornell University Methods for inhibiting fascin
EP2934144B1 (en) * 2012-12-20 2017-07-19 Merck Sharp & Dohme Corp. Indazole compounds as aldosterone synthase inhibitors
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
JP6556738B2 (ja) * 2014-01-21 2019-08-07 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ （ｒ）−１−（１−（メチルスルホニル）プロパン−２−イル）−４−（トリフルオロメチル）インドリン−５−カルボニトリルの結晶形
CA2940144C (en) 2014-02-20 2023-06-13 Cornell University Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin
CA3010847C (en) 2016-02-19 2025-09-23 Pmv Pharmaceuticals Inc Methods and compounds for restoring mutant p53 function
CN110022871A (zh) 2016-10-11 2019-07-16 拜耳制药股份公司 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品
EP3525778A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2018153898A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
DE102017008472A1 (de) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20220288091A1 (en) * 2019-03-18 2022-09-15 Lynnette K. NIEMAN Method for Improving Insulin Sensitivity
PL4034104T3 (pl) 2019-09-23 2025-11-12 Pmv Pharmaceuticals, Inc. Sposoby i związki przywracające funkcję zmutowanego p53
CA3096145A1 (en) * 2019-10-11 2021-04-11 Royal Bank Of Canada System and method of machine learning using embedding networks
CN111675646B (zh) * 2020-06-24 2023-04-07 郑州轻工业大学 利用古龙酸结晶母液制备2-氨基-3-(5-羟基吲哚)丙酸的方法
KR20230028484A (ko) 2020-06-24 2023-02-28 피엠브이 파마슈티컬스 인코포레이티드 암의 치료를 위한 병용 요법

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB705652A (en) * 1948-10-01 1954-03-17 Farbewerke Hoechst Ag Manufacture of 3-aminopropane compounds
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
JPH0977744A (ja) * 1995-09-12 1997-03-25 Kyowa Hakko Kogyo Co Ltd インドール誘導体
GB9523948D0 (en) * 1995-11-23 1996-01-24 Univ East Anglia Process for preparing n-benzyl indoles
CZ288545B6 (cs) 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
CA2356162A1 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Substituted tricyclics
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
AU2001285318A1 (en) 2000-08-28 2002-03-13 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
US6855722B2 (en) * 2001-01-29 2005-02-15 Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
DK1537078T3 (da) 2002-08-29 2010-08-02 Merck Sharp & Dohme Indoler med anti-diabetisk aktivitet
WO2004067529A1 (en) 2003-01-22 2004-08-12 Eli Lilly And Company Indole-derivative modulators of steroid hormone nuclear receptors
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
CN1960980A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为单胺再摄取调控剂治疗血管舒缩症状（vms）的杂环苯基氨基丙醇衍生物
ES2329489T3 (es) * 2004-05-03 2009-11-26 F. Hoffmann-La Roche Ag Derivados de indolilo como moduladores del receptor x del higado.
WO2005118539A1 (en) 2004-06-01 2005-12-15 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
BRPI0616459A2 (pt) * 2005-09-29 2011-06-21 Wyeth Corp compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto
MX2009006360A (es) 2006-12-12 2009-06-26 Wyeth Corp Derivados de dihidrobenzofuranilo y metodos para su uso.
JP2009077744A (ja) 2007-09-25 2009-04-16 Shinichiro Matsubara 雪上滑走板
DE102008030207A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
WO2010124114A1 (en) * 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
MX351305B (es) * 2011-01-20 2017-10-09 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides.

Also Published As

Publication number Publication date
JP2014502979A (ja) 2014-02-06
KR20140009291A (ko) 2014-01-22
US20150284376A1 (en) 2015-10-08
CN103384661A (zh) 2013-11-06
RU2598842C2 (ru) 2016-09-27
US9403807B2 (en) 2016-08-02
EP2665707A1 (en) 2013-11-27
CN103384661B (zh) 2016-08-10
EP2665707B1 (en) 2017-01-18
US20130331419A1 (en) 2013-12-12
AU2012208837A1 (en) 2013-06-27
CA2824344A1 (en) 2012-07-26
JP6078004B2 (ja) 2017-02-08
RU2013138569A (ru) 2015-02-27
ES2618812T3 (es) 2017-06-22
MX2013008431A (es) 2013-08-12
US8933113B2 (en) 2015-01-13
EP2665707A4 (en) 2015-01-14
AU2012208837B2 (en) 2016-07-28
WO2012097744A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
PH12013502204A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
TW201613864A (en) Novel compounds
GB201209587D0 (en) Therapeutic compounds
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
PH12017500089A1 (en) Aldosterone synthase inhibitors
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
NZ729688A (en) Aldosterone synthase inhibitors
UA117154C2 (uk) Антагоністи s1p3
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
PH12013500545A1 (en) Oxadiazole inhibitors of leukotriene production
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
TN2013000441A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MX2015012350A (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5ht4.
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration